{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ICLR",
  "name": "ICON plc",
  "url": "https://orbyd.app/dossiers/ICLR/",
  "json_url": "https://orbyd.app/dossiers/ICLR.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a2",
    "n": 2
  },
  "current_thesis": "Restatement discount unwinding on a CRO whose bookings stopped deteriorating: the investigation closed 2026-05-27 with 2023/2024 revenue overstated only 0.8%/1.1%, then two straight beats (Q1 06-23, Q2 07-29) with FY26 affirmed both times. Sell-side still raising (Citi $180, Truist $209 on 07-31), but RSI 48.6 and -18.9% from the 52wk high say the second beat bought no follow-through, and nothing is dated until the ~late-Oct Q3 print.",
  "invalidation_trigger": "A weekly close below $148 unwinds much of the advance dating from the 2026-06-24 Q1 reaction and puts price ~11% under the $167 average 2025 repurchase price; a Q3 2026 print (~late Oct, est.) that trims the twice-affirmed $7.850-8.150B / $10.00-11.00 FY26 frame confirms it.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "freight-logistics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Foreign private issuer: reports on Form 20-F/6-K, not 10-Q/8-K, and files no Form 4s — US insider-transaction screens return an empty set for this name.",
    "2025 Form 20-F concluded internal control over financial reporting and disclosure controls were NOT effective as of 2025-12-31; material weaknesses remain under remediation.",
    "Reporting calendar was compressed by the restatement: FY25 results 2026-05-27, Q1 2026 on 2026-06-23, Q2 2026 on 2026-07-29. Historical date comparisons will misalign.",
    "FY2025 guidance was withdrawn on 2026-02-12 during the Audit Committee investigation; the FY26 bands issued 2026-05-27 are the first guidance since.",
    "Irish-domiciled, USD-reporting company with a largely euro- and multi-currency cost base; FX moves hit margin independently of bookings."
  ],
  "body_markdown": "\nം# ICLR — ICON plc\n\n## Current Thesis\nThe leg on offer has shifted since June. What is being bought now is not just an analyst-momentum bounce off one beat, but the unwind of a restatement discount layered on a CRO bookings cycle that has stopped deteriorating. The Audit Committee investigation opened in late October 2025 closed on 2026-05-27 with the damage quantified and small: 2023 revenue overstated by $65.3M (0.8%), 2024 by $92.7M (1.1%). Two clean quarters have printed since — Q1 2026 on 2026-06-23 (adj EPS $2.50 vs $2.42, revenue $2.034B vs $1.999B) and Q2 2026 on 2026-07-29 (adj EPS $2.56 vs $2.52, revenue $2.063B vs $2.006B) — with FY26 guidance affirmed both times. Sell-side kept moving after the second beat: Citigroup lifted its Neutral target from $165 to $180 and Truist its Buy target from $207 to $209, both 2026-07-31. The problem with the tape is that none of it produced follow-through. The 2026-08-07 close of $164.51 sits 18.9% below the $202.92 52-week high with RSI(14) at 48.6, and the next dated company event is roughly eleven weeks out.\n\n## Bull Case\n- Tail risk was quantified and retired on 2026-05-27: restated overstatements of $65.3M in 2023 (0.8% of revenue) and $92.7M in 2024 (1.1%), against a market that had been trading a withdrawn-guidance blank cheque since 2026-02-12.\n- Restated FY2025 base is intact: revenue $8,251.3M, adjusted diluted EPS $12.53, net business wins $9,033M, book-to-bill 1.09, total backlog $21.8B (2026-05-27 release).\n- Two consecutive beats on both lines — 2026-06-23 and 2026-07-29 — with the FY26 frame affirmed each time at $10.00–11.00 adjusted EPS and $7.850–8.150B revenue.\n- The upgrade wave has extended rather than decayed: RBC to Outperform $185 (2026-06-25), Truist to Buy $207 (2026-06-30), then a second round of raises on 2026-07-31 after the Q2 print.\n- The company repurchased $750M of stock during 2025 at an average $167 per share (disclosed 2026-05-27). The 2026-08-07 close of $164.51 is below that average.\n- Microsoft was selected to expand AI across ICON's clinical trials (2026-06-22), an efficiency overlay on the outsourced-R&D model.\n\n## Bear Case\n- FY26 as guided is a contraction year against the restated FY2025 base: $7,850–8,150M revenue versus $8,251.3M actual, and $10.00–11.00 adjusted EPS versus $12.53. The top of the 2026 revenue band still lands below 2025.\n- The affirmed guidance sits under the Street on both lines — consensus $10.64 EPS falls in the upper part of the $10.00–11.00 band, and consensus $8.063B revenue is above the guidance midpoint zone (2026-07-29).\n- Internal control over financial reporting and disclosure controls were concluded not effective as of 2025-12-31 in the 2025 Form 20-F, with material weaknesses still under remediation. The restatement spanned Q3 2023 through Q4 2024 plus the first nine months of 2025.\n- Analyst dispersion has not compressed: B of A Underperform $150 (2026-06-25) against Truist Buy $209 (2026-07-31).\n- The 1.09 book-to-bill is a full-year 2025 figure. What confirms or kills the recovery is quarterly net new business on the 2026 calls, and that cadence has only two post-restatement observations.\n- RSI(14) at 48.6 on 2026-08-07 against roughly 65 in late June: the second beat did not extend the momentum bid it was supposed to.\n\n## Setup & Price Structure\nClose $164.51 on 2026-08-07, 18.9% under the $202.92 52-week high, with a 3-month return of +32.1% — most of that advance dates from the 2026-06-24 reaction to the Q1 print, not from the Q2 print five weeks later. The 52-week high is a pre-investigation artifact and is not a level this tape has recently traded near.\n\nLife-cycle read: **MATURING**. The re-rating began 2026-06-24, the ratings migration ran 2026-06-25 to 2026-06-30, and by 2026-07-31 the sell-side was into its second round of target raises on the same story. That is a well-known narrative that is still working, with flow moderating — the defining evidence is RSI back at 48.6 and no new high after a second beat.\n\nPositioning observables, stated as observed: sell-side coverage is dense and one-directional since 2026-06-24 (a dozen-plus target raises inside 48 hours, two rating upgrades in a week, a second raise round on 2026-07-31); retail attention spiked in that window (social velocity +342% as of 2026-06-26) and has not been refreshed by a comparable datapoint since; there is no imminent earnings date; and the issuance side runs the other way, with $750M repurchased in 2025 at an average $167. Insider-transaction screens return nothing here because ICON reports as a foreign private issuer and does not file Form 4s. The one crowding flag that is real is analyst clustering into a bull band of $185–209 while the tape holds mid-range.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-08 → 2026-09-07: no confirmed dated company catalyst.** The reporting calendar was compressed to catch up after the restatement — FY25 results 2026-05-27, Q1 2026 on 2026-06-23, Q2 2026 on 2026-07-29 — and Q3 cannot be reported before the quarter closes 2026-09-30.\n- **~2026-10-28 (est.): Q3 2026 results.** First print on a normalized calendar. Resolves whether quarterly net new business holds against the FY2025 1.09 book-to-bill and whether the $7.850–8.150B / $10.00–11.00 FY26 frame survives a third affirmation.\n- **Undated, ongoing:** material-weakness remediation progress, disclosed through periodic filings rather than on a fixed date.\n\n## What Would Change Our Mind\nThe structural break is the guidance frame, and it has one scheduled test. A Q3 2026 print (~late October, est.) that trims or abandons the twice-affirmed $7.850–8.150B revenue and $10.00–11.00 adjusted EPS bands would say the two beats were catch-up accounting cadence rather than a stabilizing bookings cycle. A quarterly book-to-bill printing below 1.0, or backlog slipping from the $21.8B disclosed 2026-05-27, does the same thing sooner in the data than in the headline.\n\nOn price, the gradeable condition is a weekly close below $148, which unwinds a substantial share of the advance dating from the 2026-06-24 reaction and puts the stock roughly 11% under the $167 average price at which the company retired $750M of its own stock in 2025.\n\nTwo secondary conditions would reinforce it: a downgrade out of the $185–209 bull cluster assembled between 2026-06-25 and 2026-07-31, which would mark the analyst leg turning; and any 6-K disclosing further material weaknesses or a widening of the 2023–2025 restatement, which reopens the discount the 2026-05-27 release was supposed to close.\n\nConversely, a weekly close that takes out the post-June range highs on expanding volume, alongside a third guidance affirmation with quarterly book-to-bill above 1.0, would move the read from recovery toward confirmed trend.\n\n## Correlation Notes\n- Direct CRO comparables: IQVIA (IQV), Medpace (MEDP), Fortrea (FTRE), Charles River (CRL). Read-throughs on bookings, cancellation rates and pharma R&D budget commentary travel across this group within a single session.\n- Upstream driver is biotech funding capacity — XBI and small/mid-cap biotech issuance windows lead CRO net new business by several quarters. One quarter of beats does not reverse that cycle.\n- Company-specific decoupling risk: the restatement history means ICLR can trade on governance headlines that have no peer analogue, in either direction.\n- Structure: Irish-domiciled, USD-reporting, ordinary shares listed on Nasdaq, filing on the 20-F/6-K schedule. US-style 10-Q cadence and Form 4 insider data do not exist for this name, so screens built on them will show a false blank.",
  "first_seen": "2026-06-26",
  "last_analyzed": "2026-08-08T15:56:14+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}